Axitinib after Sunitinib in Metastatic Renal Cancer: Preliminary Results from Italian “Real-World” SAX Study

Axitinib is an oral angiogenesis inhibitor, currently approved for treatment of metastatic renal cell carcinoma (mRCC) after failure of prior treatment with Sunitinib or cytokine. The present study is an Italian Multi-Institutional Retrospective Analysis that evaluated the outcomes of Axitinib, in s...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Front Pharmacol
Hlavní autoři: D'Aniello, Carmine, Vitale, Maria G., Farnesi, Azzurra, Calvetti, Lorenzo, Laterza, Maria M., Cavaliere, Carla, Della Pepa, Chiara, Conteduca, Vincenza, Crispo, Anna, De Vita, Ferdinando, Grillone, Francesco, Ricevuto, Enrico, De Tursi, Michele, De Vivo, Rocco, Di Napoli, Marilena, Cecere, Sabrina C., Iovane, Gelsomina, Amore, Alfonso, Piscitelli, Raffaele, Quarto, Giuseppe, Pisconti, Salvatore, Ciliberto, Gennaro, Maiolino, Piera, Muto, Paolo, Perdonà, Sisto, Berretta, Massimiliano, Naglieri, Emanuele, Galli, Luca, Cartenì, Giacomo, De Giorgi, Ugo, Pignata, Sandro, Facchini, Gaetano, Rossetti, Sabrina
Médium: Artigo
Jazyk:Inglês
Vydáno: Frontiers Media S.A. 2016
Témata:
Pharmacology
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5039205/
https://ncbi.nlm.nih.gov/pubmed/27733829
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fphar.2016.00331
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky